Abivax said its experimental treatment for ulcerative colitis showed significant efficacy in a closely watched trial, but ...

With no licensed vaccines available to protect against the Ebola virus currently spreading in the Congo, efforts are underway ...

A compound named “substance God help me” by its longtime champion could benefit from RFK Jr.'s favorable views on using ...

The FDA has missed a self-imposed deadline to ban the use of electrical shock devices in people with intellectual ...

The French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion ...

Health insurers, providers, and consumer advocates praised the Trump administration’s long-awaited fixes to the No Surprises ...

Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis ...

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation and legislation. He is also the author of the morning Pharmalittle newsletter ...

Growing legislative scrutiny across multiple states targets the corporate structure underlying most direct-to-consumer ...

Oncologists are capable of some raucous applause, but they don’t bestow it upon just anyone. Today saw one of those coveted ...

John writes about the politics of health care, and he is the author of the twice-weekly D.C. Diagnosis newsletter. You can reach John on Signal at John_Wilkerson.07. Tara covers the business of health ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...